Company: SHPH
Filing Date: 2025-02-26
Form Type: 10-K
Source: 0001493152-25-008300
Chunk: 834

Company: Shuttle Pharmaceuticals Holdings, Inc.
Filing Date: 2025-02-26
Form: 10-K
Item: Item 4
Chunk 834
---
35,287,212  
    $(34,578,101) 
    $709,152 

The
accompanying notes are an integral part of these consolidated financial statements.

F-4

Shuttle
Pharmaceuticals Holdings, Inc.

Consolidated
Statements of Cash Flows

    2024  
    2023 

    Years Ended

    December 31,

    2024  
    2023 
  
    CASH FLOWS FROM OPERATING ACTIVITIES: 

    Net loss 
    $(9,144,797) 
    $(6,592,723)
  
    Adjustments to reconcile net loss to net cash used in operating activities: 

    Depreciation 
     5,463  
     6,811 
  
    Change in fair value of derivative liabilities 
     (555,789) 
     (2,216,488)
  
    Amortization of debt discount and finance fees 
     1,079,444  
     2,123,049 
  
    Gain on marketable securities 
     (28,550) 
     (4,970)
  
    Change in fair value of marketable securities 
     —  
     (71,568)
  
    Accrued interest settled with common stock 
     54,670  
     294,927 
  
    Loss on settlement of convertible debt 
     833,501  
     477,221 
  
    Stock-based compensation 
     259,744  
     181,960 
  
    Expense for debt issuance costs due to fair value election on convertible notes 
     107,491  
     — 
  
    Expense for issuance costs due to liability classified warrants 
     28,477  
     — 
  
    Loss on issuance of convertible notes – fair value option 
     16,758  
     — 
  
    Change in fair value of convertible notes 
     (122,553) 
     — 
  
    Changes in operating assets and liabilities: 

    Accrued interest income 
     14,901  
     (14,901)
  
    Prepaid expenses 
     (176,300) 
     46,675 
  
    Accounts payable and accrued expenses 
     313,741  
     166,115 
  
    Accounts payable and accrued expenses